SCM
AXSM icon

Sio Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Sio Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-239,000
Closed -$4.84M – 73
2019
Q3 		$4.84M Buy
+239,000
New +$6.14M 1.56% 25

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sio Capital Management's AXSM Position: Q4 2019 in Review

Sio Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2019, closing a stake of 20,310 shares — an estimated $411K sold.

Sio Capital Management first reported a position in AXSM in Q1 2017 and held it in 9 quarters. The position peaked at $1.44M in Q3 2018. 169 funds tracked by Wall St. Rank hold AXSM as of Q4 2019.

  • Sio Capital Management reported no remaining Axsome Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sio Capital Management sold 20,310 Axsome Therapeutics shares in Q4 2019, an estimated $411K.
  • Sio Capital Management first reported a position in Axsome Therapeutics in Q1 2017 and held it in 9 quarters.
  • Sio Capital Management's Axsome Therapeutics position peaked at $1.44M in Q3 2018.
  • 169 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2019.

Based on Sio Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.